1. Pink Sheet
  2. >>Geography
  3. >>Asia
  4. >>South Korea

Korea Review/Outlook: Biopharma Support Policies, Regulatory Innovation In The Spotlight

Long-Awaited 'Control Tower' Kicks Off

 
• By Jung Won Shin

Steps to foster the biopharma industry, a regulatory science innovation law and a new pan-government policy control tower were among the highlights of policy and regulatory activity in South Korea in 2023 set to have an ongoing impact throughout this year. 

Han River sunrise
Ministry New Year Address Points To Ongoing Industry-Friendly Policies • Source: Shutterstock

Authorities in South Korea have emphasized the continued importance of fostering the biopharma and other health-related sectors, after stepping up regulatory innovation in 2023 to help develop them into national flagship industries and to match standards of other major regulator agencies around the world.

During last year, a series of measures including comprehensive five-year plans and market creation steps, as well as regulatory reform measures and new regulatory science innovation legislation, were announced in the country to speed

More from South Korea

More from Asia

Japan Looks To Build Domestic Capacity In New Modalities

 
• By Lisa Takagi

Japan's trade ministry is providing new support to build domestic capacity for new modalities including cell and gene therapies, as part of wider efforts to support the national bioventure ecosystem.

Pipeline To Product – What Is Driving Cell And Gene Therapy Progress In India?

 
• By Vibha Ravi

US-based Colossal Labs has claimed to bring back the dire wolf from extinction. While the science is not as dramatic in India yet, cell and gene therapies are making progress as treatments for cancer and other diseases. Pink Sheet takes a look at what is driving CGT success and growth.

Japan Identifies Drugs ‘In Urgent Need’ Of Development

 
• By Lisa Takagi

Artesunate for malaria, TB drug pretomanid and omadacycline for pneumonia and skin infections are among the drugs identified by Japanese regulatory authorities in urgent need of domestic development.